$553 Million is the total value of TANG CAPITAL MANAGEMENT LLC's 20 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 14.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ODT | Buy | ODONATE THERAPEUTICS INC | $204,657,000 | -65.7% | 15,238,782 | +8.3% | 37.03% | -36.1% |
| RCKT | ROCKET PHARMACEUTICALS INC | $67,791,000 | +9.2% | 2,965,485 | 0.0% | 12.27% | +103.3% | |
| HRTX | HERON THERAPEUTICS INC | $42,932,000 | +0.7% | 2,896,904 | 0.0% | 7.77% | +87.5% | |
| BHVN | Sell | BIOHAVEN PHARMACTL HLDG CO L | $38,947,000 | -45.7% | 599,091 | -38.9% | 7.05% | +1.1% |
| ANAB | Buy | ANAPTYSBIO INC | $38,773,000 | -31.4% | 2,628,678 | +4.0% | 7.02% | +27.7% |
| LJPC | Buy | LA JOLLA PHARMACEUTICAL CO | $37,904,000 | +2.3% | 9,405,490 | +8.2% | 6.86% | +90.4% |
| BIO | Sell | BIO RAD LABS INCcl a | $20,618,000 | -42.9% | 40,000 | -50.0% | 3.73% | +6.3% |
| RLMD | RELMADA THERAPEUTICS INC | $18,810,000 | -15.9% | 500,000 | 0.0% | 3.40% | +56.5% | |
| UTHR | Sell | UNITED THERAPEUTICS CORP DEL | $16,160,000 | -33.2% | 160,000 | -20.0% | 2.92% | +24.3% |
| SGMO | SANGAMO THERAPEUTICS INC | $14,920,000 | +5.5% | 1,578,795 | 0.0% | 2.70% | +96.4% | |
| PBYI | Sell | PUMA BIOTECHNOLOGY INC | $12,573,000 | -11.7% | 1,246,121 | -8.7% | 2.28% | +64.4% |
| CHRS | COHERUS BIOSCIENCES INC | $10,087,000 | +2.7% | 550,000 | 0.0% | 1.82% | +91.1% | |
| AVRO | Sell | AVROBIO INC | $9,114,000 | -34.7% | 700,000 | -12.5% | 1.65% | +21.5% |
| LSACU | LIFESCI ACQUISITION CORPunit 03/31/2025 | $6,800,000 | +23.6% | 500,000 | 0.0% | 1.23% | +129.9% | |
| BCTG | New | BCTG ACQUISITION CORP | $4,856,000 | – | 468,750 | +100.0% | 0.88% | – |
| EGRX | Sell | EAGLE PHARMACEUTICALS INC | $2,645,000 | -78.4% | 62,262 | -75.6% | 0.48% | -59.8% |
| VNDA | VANDA PHARMACEUTICALS INC | $1,849,000 | -15.6% | 191,426 | 0.0% | 0.34% | +57.3% | |
| PRTA | Sell | PROTHENA CORP PLC | $1,785,000 | -37.7% | 178,688 | -34.7% | 0.32% | +16.2% |
| CTMX | Sell | CYTOMX THERAPEUTICS INC | $751,000 | -69.9% | 112,880 | -62.4% | 0.14% | -44.0% |
| TENAX THERAPEUTICS INC | $708,000 | +70.2% | 460,000 | 0.0% | 0.13% | +220.0% | ||
| NCNA | Exit | NUCANA PLCsponsored adr | $0 | – | -100,000 | -100.0% | -0.05% | – |
| RDUS | Exit | RADIUS HEALTH INC | $0 | – | -119,005 | -100.0% | -0.16% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HERON THERAPEUTICS INC | 37 | Q3 2023 | 55.0% |
| LA JOLLA PHARMACEUTICAL CO | 34 | Q2 2022 | 37.1% |
| ROCKET PHARMACEUTICALS INC | 20 | Q3 2023 | 31.6% |
| BIOMARIN PHARMACEUTICAL INC | 18 | Q3 2017 | 12.1% |
| ODONATE THERAPEUTICS INC | 17 | Q4 2021 | 69.8% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 18.4% |
| COHERUS BIOSCIENCES INC | 15 | Q3 2023 | 2.7% |
| EQUILLIUM INC | 13 | Q3 2023 | 1.2% |
| RELMADA THERAPEUTICS INC | 12 | Q4 2022 | 6.2% |
| MIRATI THERAPEUTICS INC | 11 | Q3 2023 | 10.9% |
View TANG CAPITAL MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-14 |
| 4 | 2024-02-02 |
| 4 | 2023-12-18 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-10-13 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-06-01 |
| 4 | 2023-06-01 |
| 4 | 2023-05-30 |
View TANG CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.